Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04590898 · ClinicalTrials.gov registry record

Peri-device Leakage Closure After LAAO

A clinical trial of Stroke and Atrial Fibrillation, sponsored by Cardiovascular Center Frankfurt.

Completed
Registry status
85
Enrollment target
16
Study locations

NCT04590898: Completed study of Stroke and Atrial Fibrillation, sponsored by Cardiovascular Center Frankfurt.

NCT04590898 is a study of Stroke and Atrial Fibrillation that has completed, run by Cardiovascular Center Frankfurt. The registered enrollment target is 85 participants, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (99% lower). The trial reports 16 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04590898, a study of Stroke and Atrial Fibrillation, has completed, sponsored by Cardiovascular Center Frankfurt.

COMPLETED
Registry status
85 participants
Enrollment target
16
Study locations

Study Summary

The investigators thought to evaluate the safety and feasibility of peri-device leakage closure after left atrial appendage occlusion (LAAO, either surgical or interventional) with different devices.

Primary Outcome

Rate of all-cause mortality during the index procedure, number of participants experiencing a procedure-related death within 30days or during in-hospital stay for the index procedure (if\>30days)

Interventions

  • DEVICE Peri-device leakage closure after left atrial appendage occlusion

Study Locations (16)

Other

  • Aarhus University Hospital - Aarhus
  • Rigshospitalet Copenhagen - Copenhagen
  • Universitätsmedizin Berlin - Campus Benjamin Franklin (CBF) - Berlin
  • Poznan University of Medical Sciences - Poznan
  • Hospital Universitario de Salamanca - Salamanca
  • Inselspital Bern - Bern
  • Nuffield Health - Headington

Arizona

  • • Banner University Medical Center Phoenix - Phoenix

California

  • Scripps Health - La Jolla

Kansas

  • Kansas City Heart Rhythm Institute - Overland Park

Minnesota

  • Mayo Clinic Hospital - Saint Mary's Campus - Rochester

Tennessee

  • Vanderbilt Heart Institute - Nashville

Texas

  • Austin Heart - Austin

Utah

  • University of Utah Hospital - Salt Lake City

Trial Details

FieldValue
Enrollment Target 85 participants
Start Date 2020-09-27
Est. Completion 2021-09-01
Cardiovascular Center Frankfurt

1 total trials

What the finished NCT04590898 record still lists

NCT04590898 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 85 participants, a relatively small participant target, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (99% lower).

The record links to 4 conditions, with Stroke appearing as the primary indexed condition, and to 1 intervention - of which Peri-device leakage closure after left atrial appendage occlusion is the first listed.

NCT04590898 lists 16 locations in 10 states (Other, Arizona, California).

Frequently Asked Questions

What is clinical trial NCT04590898 about?

NCT04590898 is a clinical study titled "Peri-device Leakage Closure After LAAO". The investigators thought to evaluate the safety and feasibility of peri-device leakage closure after left atrial appendage occlusion (LAAO, either surgical or interventional) with different devices.

What is the current status of trial NCT04590898?

This trial is currently completed. The enrollment target is 85 participants. The study started on 2020-09-27. Estimated completion is 2021-09-01.

What conditions does trial NCT04590898 study?

This clinical trial studies the following conditions: Stroke, Atrial Fibrillation, Bleeding, Leakage of Cardiac Device.

What interventions are being tested in trial NCT04590898?

The interventions under investigation include: Peri-device leakage closure after left atrial appendage occlusion (DEVICE).

Who is sponsoring clinical trial NCT04590898?

This trial is sponsored by Cardiovascular Center Frankfurt, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04590898 being conducted?

This trial has 16 study locations across Arizona, California, Kansas, Minnesota, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stroke

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04590898's enrollment target sits among peer trials

85 162nd of 454 higher than 292 of 454 other Stroke trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00842283 · 85 participants

    Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target

  • NCT02133196 · 85 participants · Phase 2

    T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

  • NCT03823144 · 85 participants · NA

    Intravital Microscopy in Human Solid Tumors

  • NCT03875638 · 85 participants · Phase 2

    Treating Hyperexcitability in AD With Levetiracetam

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04590898, the US trial registry maintained by the National Library of Medicine. NCT04590898 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.